Loading...
XLONSCLP
Market cap132mUSD
Jan 03, Last price  
10.25GBP
1D
-2.38%
1Q
-22.64%
Jan 2017
-29.02%
IPO
18.30%
Name

Scancell Holdings PLC

Chart & Performance

D1W1MN
XLON:SCLP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.88%
Rev. gr., 5y
%
Revenues
0k
-100.00%
000000000000005,271,0000
Net income
-6m
L-50.91%
-786,000-1,737,000-1,649,000557,058-1,901,944-2,222,954-2,414,630-2,583,273-3,544,979-4,194,509-5,627,487-5,506,000-15,477,000-2,065,000-11,936,000-5,859,000
CFO
-16m
L+92.38%
-1,059,000-1,314,000-1,777,000859,620-1,998,331-2,093,367-2,638,747-2,330,744-3,847,466-4,062,747-7,017,947-7,032,949-4,772,000-7,803,000-8,140,000-15,660,000
Earnings
Jan 28, 2025

Profile

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
URL
https://www.scancell.co.uk/
IPO date
Jul 30, 2010
Employees
40
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
5,271
 
Cost of revenue
13,837
17,191
15,004
Unusual Expense (Income)
NOPBT
(13,837)
(11,920)
(15,004)
NOPBT Margin
Operating Taxes
(3,258)
(2,368)
(1,703)
Tax Rate
NOPAT
(10,579)
(9,552)
(13,301)
Net income
(5,859)
-50.91%
(11,936)
478.01%
(2,065)
-86.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,989
166
24,136
BB yield
-15.58%
-0.13%
-20.77%
Debt
Debt current
2,034
306
208
Long-term debt
18,726
20,279
15,518
Deferred revenue
Other long-term liabilities
2,860
14,000
12,031
Net debt
5,943
665
(25,384)
Cash flow
Cash from operating activities
(15,660)
(8,140)
(7,803)
CAPEX
(177)
(203)
(744)
Cash from investing activities
178
81
(741)
Cash from financing activities
10,390
(746)
46,079
FCF
(11,192)
(11,071)
(14,960)
Balance
Cash
14,817
19,920
41,110
Long term investments
Excess cash
14,817
19,656
41,110
Stockholders' equity
(83,258)
(71,414)
(44,844)
Invested Capital
102,479
98,515
91,751
ROIC
ROCE
EV
Common stock shares outstanding
862,484
816,368
815,535
Price
0.09
-43.00%
0.16
9.82%
0.14
-35.23%
Market cap
76,934
-39.78%
127,762
9.94%
116,214
-22.19%
EV
82,877
128,427
90,830
EBITDA
(12,871)
(11,018)
(14,755)
EV/EBITDA
Interest
1,089
1,215
2,882
Interest/NOPBT